Predictors of loss to follow-up in patients living with hiv/aids after initiation of antiretroviral therapy

North American Journal of Medical Sciences

Volumn 6, Issue 9, 2014, Pages 453-459

  Berheto, Tezera Moshago ^a   Haile, Demissew Berihun ^b   Mohammed, Salahuddin ^b  

^a Department of Public Health Aman College of Health Sciences   (Ethiopia)

^b MIZAN TEPI UNIVERSITY   (Ethiopia)

Author keywords

AIDS; Anti retroviral therapy; CD4; Cohort; Ethiopia; HIV; Lost to follow up; Mizan Teferi; Predictors

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREGNANCY; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; TUBERCULOSIS;

EID: 84907912216     PISSN: 22501541     EISSN: 19472714     Source Type: Journal    
DOI: 10.4103/1947-2714.141636     Document Type: Article

References (38)

1. WHO. Global update on HIV treatment: Results, impact and opportunities, 2013. (Accessed March 14, 2014 at: http://www.who.int/about/licensing/copyright_form/en/index.html).
2. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individualson combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet 2008;372:293-9.
3. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, Yiannoutsos CT, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: Experience from western Kenya. AIDS 2006;20:41-8.
4. Hogg RS, Heath K, Bangsberg D, Yipa B, Press N, O’Shaughnessy MV, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002;16:1051-8.
5. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, et al. Epidemiology of human immunodeficiency virus associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30:S5-14.
6. Low-Beer S, Yip B, O’Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000;23:360-1.
7. Taiwo B. Understanding transmitted HIV resistance through the experience in the USA. Int J Infect Dis 2009;13:552-9.
8. Dalal RP, Macphail C, Mqhayi M, Wing J, Feldman C, Chersich MF, et al. Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2008;47:101-7.
9. Brennan AT, Maskew M, Sanne I, Fox MP. The importance of clinic attendance in the first six months on antiretroviral treatment: A retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc 2010;13:49.
10. Bygrave H, Kranzer K, Hilderbrand K, Whittall J, Jouquet G, Goemaere E, et al. Trends in loss to follow-up among migrant workers on antiretroviral therapy in a community cohort in Lesotho. PLoS One 2010;5:e13198.
11. Adam BD, Maticka-Tyndale E, Cohen JJ. Adherence practices among people living with HIV. AIDS Care 2003;15:263-74.
12. Malcolm SE, Ng JJ, Rosen RK, Stone VE. An examination of HIV/AIDS patients who have excellent adherence to HAART. AIDS Care 2003;15:251-61.
13. Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR. Adolescent Medicine HIV/AIDS Research Network. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 2003;157:249-55.
14. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: Systematic review and meta-analysis. PLoS One 2009;4:e5790.
15. Fatti G, Meintjes G, Shea J, Eley B, Grimwood A. Improved survival and antiretroviral treatment outcomes in adults receiving community-based adherence support: 5-year results from a multicentre cohort study in South Africa. J Acquir Immune Defic Syndr 2012;61:e50-8.
16. Amuron B, Namara G, Birungi J, Nabiryo C, Levin J, Grosskurth H, et al. Mortality and loss to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health 2009;9:290.
17. Alvarez-Uria G, Naik PK, Pakam R, Midde M. Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: Data from an HIV cohort study in India. Glob Health Action 2013;6:21682.
18. Lanoy E, Mary-Krause M, Tattevin P, Dray-Spira R, Duvivier C, Fischer P, et al. Clinical Epidemiology Group of French Hospital Database on HIV Infection. Predictors identified for losses to follow-up among HIV-sero positive patients. J Clin Epidemiol 2006;59:829-35.
19. Bagchi S. Telemedicine in rural India. PLoS Med 2006;3:e82.
20. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: A systematic review. PLoS Med 2007;4:e298.
21. Karcher H, Omondi A, Odera J, Kunz A, Harms G. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health 2007;12:687-94.
22. Central Statistical Agency [Ethiopia] and ICF International: Ethiopia Demographic and Health Survey. Addis Ababa, Ethiopia and Calverton, Maryland, USA: Central Statistical Agency and ICF International, 2012. (Accessed February 25, 2014, at http://www.usaid.gov/sites/default/files/documents/1860/Demographic%20Health%20Survey%20 2011%20Ethiopia%20Final%20Report.pdf).
23. Moshago T, Haile DB, Enqusilasie F. Survival analysis of HIV infected people on antiretroviral therapy at Mizan-Aman General Hospital, Southwest Ethiopia. Int J Sci Res 2014;3:1462-9.
24. Bakand C, Birungi J, Mwesigwa R, Nachega J, Chan K, Palmer A, et al. Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: Findings from a nationally representative cohort in Uganda. PLoS One 2011;6:e19261.
25. Deribe K, Hailekiros F, Biadgilign S, Amberbir A, Beyene BK. Defaulters from antiretroviral treatment in Jimma University Specialized Hospital, Southwest Ethiopia. Trop Med Int Health 2008;13:328-33.
26. Schoni-Affolter F, Keiser O, Mwango A, Stringer J, Ledergerber B, Mulenga L, et al. Swiss HIV Cohort Study, IeDEA Southern Africa. Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: The effect of the competing risk of death in Zambia and Switzerland. PLoS One 2011;6:e27919.
27. Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, Schouten EJ, et al. True outcomes for patients on antiretroviral therapy who are ‘‘lost to follow-up’’ in Malawi. Bull World Health Organ 2007;85:550-4.
28. Alemu AW, San Sebastian M. Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia. Glob Health Action 2010;3.
29. Gerver SM, Chadborn TR, Ibrahim F, Vatsa B, Delpech VC, Easterbrook PJ. High rate of loss to clinical follow up among African HIV-infected patients attending a London clinic: A retrospective analysis of a clinical cohort. J Int AIDS Soc 2010;13:29.
30. Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, et al. EuroSIDA study group. Loss to follow-up in an international, multicentre observational study. HIV Med 2008;9:261-9.
31. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: Patients’ response, survival, and drug resistance. Lancet 2002;360:34-40.
32. Wilson CM, Wright PF, Safrit JT, Rudy B. Epidemiology of HIV infection and risk in adolescents and youth. J Acquir Immune Defic Syndr 2010;54:S5-6.
33. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M. Adolescent medicine HIV/AIDS research network. Antiretroviral medication adherence among REACH HIV-infected adolescent cohort in the USA. AIDS Care 2001;13:27-40.
34. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Socio demographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999;13:1763-9.
35. Brinkhof MW, Spycher BD, Yiannoutsos C, Weigel R, Wood R, Messou E, et al. Adjusting mortality for loss to follow-up: Analysis of five ART programmes in sub-Saharan Africa. PLoS One 2010;5:e14149.
36. Geng EH, Glidden DV, Emenyonu N, Musinguzi N, Bwana MB, Neilands TB, et al. Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa. Trop Med Int Health 2010;15:63-9.
37. Lebouche B, Yazdanpanah Y, Gerard Y, Sissoko D, Ajana F, Alcaraz I, et al. Incidence rate and risk factors for loss to follow-up in a French clinical cohort of HIV-infected patients from January 1985 to January 1998. HIV Med 2006;7:140-5.
38. Ministry of Health (MOH) of Ethiopia: Guideline for implementation of antiretroviral therapy. Federal HIV/AIDS Prevention and Control Office. Federal Ministry of Health, 2010. (Accessed March 25, 2014, at http://www.etharc.org/…/SPM%20II%20Final%20version%20sept%2026.pdf).